Smithfield Trust Co Cuts Holdings in Stryker Co. (NYSE:SYK)

Smithfield Trust Co reduced its position in shares of Stryker Co. (NYSE:SYKFree Report) by 3.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,701 shares of the medical technology company’s stock after selling 56 shares during the quarter. Smithfield Trust Co’s holdings in Stryker were worth $504,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Farmers & Merchants Trust Co of Chambersburg PA raised its holdings in shares of Stryker by 203.3% during the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 61 shares during the last quarter. Rogco LP purchased a new position in Stryker during the fourth quarter worth approximately $30,000. HBC Financial Services PLLC acquired a new position in shares of Stryker during the 4th quarter valued at about $37,000. Bourgeon Capital Management LLC purchased a new stake in shares of Stryker in the 4th quarter valued at approximately $37,000. Finally, Operose Advisors LLC grew its position in Stryker by 308.6% in the third quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock worth $39,000 after acquiring an additional 108 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.50% of the stock is owned by insiders.

Stryker Stock Down 0.1 %

Shares of SYK traded down $0.21 during midday trading on Friday, reaching $330.65. The stock had a trading volume of 1,307,925 shares, compared to its average volume of 1,327,286. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.71 and a quick ratio of 0.99. The company has a market cap of $125.96 billion, a price-to-earnings ratio of 37.78, a PEG ratio of 2.54 and a beta of 0.91. The company’s fifty day simple moving average is $345.24 and its two-hundred day simple moving average is $318.99.

Stryker (NYSE:SYKGet Free Report) last issued its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.14. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The business had revenue of $5.24 billion during the quarter, compared to the consensus estimate of $5.10 billion. During the same quarter in the previous year, the firm earned $2.14 EPS. The company’s revenue was up 9.7% compared to the same quarter last year. Equities research analysts expect that Stryker Co. will post 11.94 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be issued a $0.80 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.97%. Stryker’s payout ratio is 36.53%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on SYK shares. TD Cowen raised their price objective on Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Stifel Nicolaus upped their price objective on shares of Stryker from $350.00 to $375.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. UBS Group lifted their target price on shares of Stryker from $339.00 to $351.00 and gave the company a “neutral” rating in a report on Wednesday, May 1st. Citigroup raised their price target on Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, Roth Mkm boosted their price objective on Stryker from $348.00 to $405.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $365.94.

View Our Latest Research Report on SYK

Stryker Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

See Also

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKFree Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.